4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Keymed Biosciences Inc. (2162) operates in the Biotechnology industry and is headquartered in Chengdu, China with about 1,768 employees. Its market capitalization is roughly HK$24 billion. In the fiscal year ended 2025-12-31, 2162 reported CNY 716M in revenue and (CNY 523M) in net income.
Keymed Biosciences Inc., a biotechnology company, engages in the discovery and development of biological therapies in the autoimmune and oncology therapeutic areas in Mainland China, the United States, and the United Kingdom.
Interactive charts & full statements → Open the 2162 valuation workbench →
| Income statement | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Revenue | CNY 716M | CNY 428M | CNY 354M | CNY 100M | — |
| Gross Profit | CNY 628M | CNY 416M | CNY 317M | CNY 98M | — |
| Operating Income (EBIT) | (CNY 548M) | (CNY 586M) | (CNY 435M) | (CNY 478M) | — |
| Net Income | (CNY 523M) | (CNY 515M) | (CNY 359M) | (CNY 308M) | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Total Assets | CNY 4.2B | CNY 3.8B | CNY 3.9B | CNY 3.9B | — |
| Total Liabilities | CNY 1.4B | CNY 1.3B | CNY 896M | CNY 593M | — |
CNY; CNYM / CNYB as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive 2162 viewer.
About TickerBase · Data methodology & sources · Privacy · Terms